Mutational characterization of HBV reverse transcriptase gene and the genotype-phenotype correlation of antiviral resistance among Chinese chronic hepatitis B patients

References

• European Association for the Study of the Liver. Electronic address: [email protected]; European Association for the study of the liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–398.
   PubMed Web of Science ®Google Scholar
• Stanaway JD, Flaxman AD, Naghavi M, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the global burden disease study 2013. Lancet. 2016;388:1081–1088.
   PubMed Web of Science ®Google Scholar
• Pacheco SR, Dos Santos M, Stocker A, et al. Genotyping of HBV and tracking of resistance mutations in treatment-naive patients with chronic hepatitis B. Infect Drug Resist. 2017;10:201–207.
   PubMed Web of Science ®Google Scholar
• Zoulim F, Locarnini S. Management of treatment failure in chronic hepatitis B. J Hepatol. 2012;56(Suppl 1):S112–S122.
   PubMed Web of Science ®Google Scholar
• Gupta N, Goyal M, Wu CH, et al. The molecular and structural basis of HBV-resistance to nucleos(t)ide analogs. J Clin Transl Hepatol. 2014;2:202–211.
   PubMedGoogle Scholar
• Tong S, Revill P. Overview of hepatitis B viral replication and genetic variability. J Hepatol. 2016;64:S4–16.
   PubMed Web of Science ®Google Scholar
• Banerjee P, Chakraborty A, Mondal RK, et al. HBV quasispecies composition in Lamivudine-failed chronic hepatitis B patients and its influence on virological response to Tenofovir-based rescue therapy. Sci Rep. 2017;7:44742.
   PubMed Web of Science ®Google Scholar
• Kim JE, Lee SY, Kim H, et al. Naturally occurring mutations in the reverse transcriptase region of hepatitis B virus polymerase from treatment-naive Korean patients infected with genotype C2. World J Gastroenterol. 2017;23:4222–4232.
   PubMed Web of Science ®Google Scholar
• Nishijima N, Marusawa H, Ueda Y, et al. Dynamics of hepatitis B virus quasispecies in association with nucleos(t)ide analogue treatment determined by ultra-deep sequencing. PLoS One. 2012;7:e35052.
   PubMed Web of Science ®Google Scholar
• Qian F, Zou W, Qin J, et al. Naturally occurring genotypic drug-resistant mutations of HBV in Huzhou, China: a single-center study. Infect Drug Resist. 2017;10:507–509.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Liao Y, Cai B, et al. Incidence of natural resistance mutations in naive chronic hepatitis B patients: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2015;30:252–261.
   PubMed Web of Science ®Google Scholar
• Ismail AM, Samuel P, Eapen CE, et al. Antiviral resistance mutations and genotype-associated amino acid substitutions in treatment-naive hepatitis B virus-infected individuals from the Indian subcontinent. Intervirology. 2012;55:36–44.
   PubMed Web of Science ®Google Scholar
• Ahn SH, Park YK, Park ES, et al. The impact of the hepatitis B virus polymerase rtA181T mutation on replication and drug resistance is potentially affected by overlapping changes in surface gene. J Virol. 2014;88:6805–6818.
   PubMed Web of Science ®Google Scholar
• Liu BM, Li T, Xu J, et al. Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naive Chinese patients. Antiviral Res. 2010;85:512–519.
   PubMed Web of Science ®Google Scholar
• Morikami K, Nakai T, Kidera A, et al. Presto (protein engineering simulator): A vectorized molecular mechanics program for biopolymers. Comput Chem. 1992;16:243–248.
   Google Scholar
• Yang J, Yan R, Roy A, et al. The I-TASSER Suite: protein structure and function prediction. Nat Methods. 2015;12:7–8.
   PubMed Web of Science ®Google Scholar
• Nguyen MH, Trinh HN, Garcia RT, et al. Prevalence of HBV DNA polymerase (B-DNA Pol) mutations in 345 patients with treatment-naive chronic hepatitis B (CHB). Gastroenterology. 2008;134:A-310.
   Web of Science ®Google Scholar
• Vutien P, Trinh HN, Garcia RT, et al. Mutations in HBV DNA polymerase associated with nucleos(t)ide resistance are rare in treatment-naive patients. Clin Gastroenterol Hepatol. 2014;12:1363–1370.
   PubMed Web of Science ®Google Scholar
• Chuaypen N, Payungporn S, Poovorawan K, et al. Next generation sequencing identifies baseline viral mutants associated with treatment response to pegylated interferon in HBeAg-positive chronic hepatitis B. Virus Genes. 2019;55:610–618.
   PubMed Web of Science ®Google Scholar
• Fu Y, Zeng Y, Chen T, et al. Characterization and clinical significance of natural variability in hepatitis B virus reverse transcriptase in treatment-naive Chinese patients by Sanger sequencing and next-generation sequencing. J Clin Microbiol. 2019;57:e00119–19.
   PubMed Web of Science ®Google Scholar
• Fan J, Zhang Y, Xiong H, et al. Nucleotide analogue-resistant mutations in hepatitis B viral genomes found in hepatitis B patients. J Gen Virol. 2015;96:663–670.
   PubMed Web of Science ®Google Scholar
• Guo X, Wu J, Wei F, et al. Trends in hepatitis B virus resistance to nucleoside/nucleotide analogues in North China from 2009-2016: a retrospective study. Int J Antimicrob Agents. 2018;52:201–209.
   PubMed Web of Science ®Google Scholar
• Svicher V, Gori C, Trignetti M, et al. The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes. J Hepatol. 2009;50:461–470.
   PubMed Web of Science ®Google Scholar
• Chen X, Gao J, Ji Z, et al. A description of the hepatitis B virus genomic background in a high-prevalence area in China. Virol J. 2014;11:101.
   PubMed Web of Science ®Google Scholar
• Inoue J, Ueno Y, Wakui Y, et al. Four-year study of lamivudine and Adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern. J Viral Hepat. 2011;18:206–215.
   PubMed Web of Science ®Google Scholar
• Langley DR, Walsh AW, Baldick CJ, et al. Inhibition of hepatitis B virus polymerase by entecavir. J Virol. 2007;81:3992–4001.
   PubMed Web of Science ®Google Scholar
• Li X, Liu Y, Xin S, et al. Comparison of detection rate and mutational pattern of drug-resistant mutations between a large cohort of genotype B and genotype C hepatitis B virus-infected patients in North China. Microb Drug Resist. 2017;23:516–522.
   PubMed Web of Science ®Google Scholar
• Mirandola S, Sebastiani G, Rossi C, et al. Genotype-specific mutations in the polymerase gene of hepatitis B virus potentially associated with resistance to oral antiviral therapy. Antiviral Res. 2012;96:422–429.
   PubMed Web of Science ®Google Scholar
• Li XG, Liu BM, Xu J, et al. Discrepancy of potential antiviral resistance mutation profiles within the HBV reverse transcriptase between nucleos(t)ide analogue-untreated and -treated patients with chronic hepatitis B in a hospital in China. J Med Virol. 2012;84:207–216.
   PubMed Web of Science ®Google Scholar
• Bayliss J, Yuen L, Rosenberg G, et al. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B. Gut. 2017;66:2013–2023.
   PubMed Web of Science ®Google Scholar
• Liu F, Chen L, Yu DM, et al. Evolutionary patterns of hepatitis B virus quasispecies under different selective pressures: correlation with antiviral efficacy. Gut. 2011;60:1269–1277.
   PubMed Web of Science ®Google Scholar
• Ji D, Liu Y, Li L, et al. The rtL229 substitutions in the reverse transcriptase region of hepatitis B virus (HBV) polymerase are potentially associated with lamivudine resistance as a compensatory mutation. J Clin Virol. 2012;54:66–72.
   PubMed Web of Science ®Google Scholar
• Qin B, Zhou Y, Zhou G, et al. Substitutions of rtL228 and/or L229 are involved in the regulation of replication and HBsAg secretion in hepatitis B virus, and do not affect susceptibility to nucleos(t)ide analogs. Mol Med Rep. 2017;16:9678–9684.
   PubMed Web of Science ®Google Scholar
• Jr HR, Miller TG, Kelley CM. Delaney WE 4th, Locarnini SA, Isom HC. In vitro study of the effects of precore and lamivudine-resistant mutations on hepatitis B virus replication. J Virol. 2007;81:3068–3076.
   PubMed Web of Science ®Google Scholar
• Li W, Warner N, Sozzi V, et al. Hepatitis B virus genotype C encoding resistance mutations that emerge during Adefovir dipivoxil therapy: in vitro replication phenotype. Hepatol Int. 2013;7:443–450.
   PubMed Web of Science ®Google Scholar
• Yang H, Westland C, Xiong S. Delaney WE 4th. In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector. Antiviral Res. 2004;61:27–36.
   PubMed Web of Science ®Google Scholar
• Walsh AW, Langley DR, Colonno RJ, et al. Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir. PLoS One. 2010;5:e9195.
   PubMed Web of Science ®Google Scholar
• Baldick CJ, Tenney DJ, Mazzucco CE, et al. Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance. Hepatology. 2008;47:1473–1482.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhou Y, Li X, et al. Hepatitis B virus mutation pattern rtL180M + A181C + M204V may contribute to entecavir resistance in clinical practice. Emerg Microbes Infect. 2019;8:354–365.
   PubMed Web of Science ®Google Scholar
• Hayashi S, Murakami S, Omagari K, et al. Characterization of novel entecavir resistance mutations. J Hepatol. 2015;63:546–553.
   PubMed Web of Science ®Google Scholar